Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / articles / INCY - Goldman Sachs Downgrades Incyte Amid Concerns Over Jakafi Studies Competitiveness | Benzinga

INCY - Goldman Sachs Downgrades Incyte Amid Concerns Over Jakafi Studies Competitiveness | Benzinga

Incyte Corporation

Goldman Sachs downgraded Incyte Corp (NASDAQ: INCY), citing continued uncertainty around Jakafi (Ruxolitinib) lifecycle management ahead of the mid-27/late-28 EU/US losses-of-exclusivity (LOEs). 

Goldman Sachs seeks clarity on once-daily Jakafi that received an FDA complete response letter for certain types of myelofibrosis, polycythemia vera, and graft-versus-host disease.

Discussions with the FDA are ongoing, and INCY has noted that the most likely scenario would require a modified formulation and potentially a two-year delay with potential approval in 2026/2027.

The analyst downgraded the stock to Neutral from Buy, with the Full story available on Benzinga.com
Stock Information
Company Name: Incyte Corporation
Stock Symbol: INCY
Market: NASDAQ
Website: incyte.com
Menu
INCY INCY Quote INCY Short INCY News INCY Articles INCY Message Board
Get INCY Alerts

News, Short Squeeze, Breakout and More Instantly...